News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 04:29:53 16/06/26 am AEST			5-day change	1st Jan Change
24.54 ^USD	-2.15%		-0.99%	-20.28%

02:57pm	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
14/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI

All News

Mentions Relevance

02:05am	Major Shareholder Announcement	GL
02:04am	Major Shareholder Announcement	AQ
12:16am	Genmab A/S : has published its Articles of Association	PU
14/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	BU
14/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	GL
14/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI
12/06	Grant of Restricted Stock Units and Warrants to Employees in Genmab	GL
12/06	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
12/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	BU
12/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	GL
12/06	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
30/05	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress	AQ
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	BU
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	GL
18/05	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
13/05	Genmab A/S : Articles of association dated May 12, 2026 – English	PU
13/05	Genmab A/S : has published its Articles of Association	PU
13/05	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
12/05	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
12/05	Genmab - Major Shareholder Announcement	AQ
11/05	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW
09/05	Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis
09/05	Genmab says Orbis Investment Management Limited holds 5.08% of Genmab A/S as of May 8, 2026	RE
09/05	Major Shareholder Announcement	GL